PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17322140-2	2007	In human liver microsomes, the mean 50% inhibitory concentrations (IC(50)) for PJ and GFJ versus CYP3A (triazolam alpha-hydroxylation) were 0.61% and 0.55%, (v/v) respectively, without preincubation of inhibitor with microsomes.	Triazolam	104-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-102
18076219-19	2008	Dosage adjustments may be required for drugs that are substrates of CYP3A4 (e.g. ciclosporin, triazolam) and CYP2C19 enzymes (e.g. diazepam, phenytoin) when administered with armodafinil.	Triazolam	94-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-74
17523050-7	2007	Testosterone 2alpha- and 16alpha-hydroxylation reactions were conducted primarily by CYP2C11, and midazolam 4-hydroxylation and triazolam 1"-hydroxylation were preferentially catalyzed by CYP3A1/2, but specificity was otherwise generally poor.	Triazolam	128-137	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	188-196
17178770-9	2007	The mutants also greatly decreased the metabolism of testosterone, erythromycin, nevirapine, and triazolam relative to those activities of CYP3A7 wild-type enzyme.	Triazolam	97-106	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	139-145
15470333-9	2004	Estimates of CYP3A-mediated extraction by the intestine and liver indicated approximately equal contributions by both organs but larger values for midazolam than for triazolam, and these differences accounted for the differences in oral bioavailability, 30% +/- 13% versus 55% +/- 20%, respectively.	Triazolam	166-175	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-18
17204458-0	2007	Theoretical calculation of triazolam hydroxylation and endogenous steroid inhibition in the active site of CYP3A4.	Triazolam	27-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	107-113
17204458-2	2007	CYP3A4 produced more 4-hydroxytriazolam than alpha-hydroxytriazolam at concentrations of more than 60 muM triazolam, and different steroids had different inhibitory effects on the system.	Triazolam	30-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
16251267-6	2006	With triazolam, relative rCBF of the left orbital basal forebrain decreased more during stage 2 than slow wave sleep, whereas absolute CBF of the occipital cortex and cerebral white matter remained constant.	Triazolam	5-14	CCAAT enhancer binding protein zeta	Homo sapiens	26-29
16251267-7	2006	During triazolam-induced stage 2 sleep, absolute CBF of the cerebral white matter correlated more strongly to both MAP and Paco2 than during placebo sleep and also correlated more strongly to both MAP and Paco2 than absolute CBF of the occipital cortex.	Triazolam	7-16	CCAAT enhancer binding protein zeta	Homo sapiens	49-52
16251267-7	2006	During triazolam-induced stage 2 sleep, absolute CBF of the cerebral white matter correlated more strongly to both MAP and Paco2 than during placebo sleep and also correlated more strongly to both MAP and Paco2 than absolute CBF of the occipital cortex.	Triazolam	7-16	CCAAT enhancer binding protein zeta	Homo sapiens	225-228
16251267-8	2006	In the frontal white matter, during triazolam-induced stage 2 sleep compared to wakefulness, absolute CBF was significantly better correlated to MAP, but not to Paco2.	Triazolam	36-45	CCAAT enhancer binding protein zeta	Homo sapiens	102-105
16251267-9	2006	During triazolam-induced stage 2, the cerebral white matter may receive a modulated CBF regulation having the strengthened relationship of Paco2 to CBF and, more locally, the frontal white matter may depend precariously on CBF regulation.	Triazolam	7-16	CCAAT enhancer binding protein zeta	Homo sapiens	84-87
16251267-9	2006	During triazolam-induced stage 2, the cerebral white matter may receive a modulated CBF regulation having the strengthened relationship of Paco2 to CBF and, more locally, the frontal white matter may depend precariously on CBF regulation.	Triazolam	7-16	CCAAT enhancer binding protein zeta	Homo sapiens	148-151
16251267-9	2006	During triazolam-induced stage 2, the cerebral white matter may receive a modulated CBF regulation having the strengthened relationship of Paco2 to CBF and, more locally, the frontal white matter may depend precariously on CBF regulation.	Triazolam	7-16	CCAAT enhancer binding protein zeta	Homo sapiens	148-151
15764714-5	2005	CYP3A inhibition was tested using triazolam hydroxylation in human liver microsomes (HLM).	Triazolam	34-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-5
15863898-5	2005	Nicardipine strongly inhibited two-pathways of triazolam hydroxylation both catalyzed by CYP3A4.	Triazolam	47-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95
15386482-4	2004	The three compounds were also evaluated as potential inhibitors of human CYP3A based on an in vitro model using triazolam hydroxylation by human liver microsomes as an index reaction.	Triazolam	112-121	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-78
15470333-12	2004	CONCLUSION: Despite alprazolam, midazolam, and triazolam having markedly different pharmacokinetic characteristics, statistically significant correlations were present between the oral and systemic clearances of the 3 drugs, consistent with a major involvement of CYP3A in their metabolism and elimination.	Triazolam	47-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	264-269
15482640-5	2004	In rats treated with MPS, an in-situ efflux experiment using rhodamine-123 demonstrated that the reverse transport function of P-glycoprotein (P-gp) in the small intestine was significantly enhanced, although there was no significant increase in the intestinal microsomal activity of triazolam alpha- and 4-hydroxylation, metabolic probes for CYP3A.	Triazolam	284-293	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	127-141
15482640-5	2004	In rats treated with MPS, an in-situ efflux experiment using rhodamine-123 demonstrated that the reverse transport function of P-glycoprotein (P-gp) in the small intestine was significantly enhanced, although there was no significant increase in the intestinal microsomal activity of triazolam alpha- and 4-hydroxylation, metabolic probes for CYP3A.	Triazolam	284-293	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	143-147
15258104-0	2004	Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice.	Triazolam	15-24	phosphoglycolate phosphatase	Mus musculus	45-59
15258104-1	2004	The role of P-glycoprotein (P-gp) on the distribution of the benzodiazepine triazolam (TRZ) and the azole antifungal agent ketoconazole (KET), and on the TRZ-KET interaction, was studied using mdr1a(-) or mdr1a/b(-/-) mice (P-gp-deficient mice) and matched controls.	Triazolam	76-85	phosphoglycolate phosphatase	Mus musculus	12-26
15258104-1	2004	The role of P-glycoprotein (P-gp) on the distribution of the benzodiazepine triazolam (TRZ) and the azole antifungal agent ketoconazole (KET), and on the TRZ-KET interaction, was studied using mdr1a(-) or mdr1a/b(-/-) mice (P-gp-deficient mice) and matched controls.	Triazolam	76-85	phosphoglycolate phosphatase	Mus musculus	28-32
15258104-1	2004	The role of P-glycoprotein (P-gp) on the distribution of the benzodiazepine triazolam (TRZ) and the azole antifungal agent ketoconazole (KET), and on the TRZ-KET interaction, was studied using mdr1a(-) or mdr1a/b(-/-) mice (P-gp-deficient mice) and matched controls.	Triazolam	87-90	phosphoglycolate phosphatase	Mus musculus	12-26
15258104-1	2004	The role of P-glycoprotein (P-gp) on the distribution of the benzodiazepine triazolam (TRZ) and the azole antifungal agent ketoconazole (KET), and on the TRZ-KET interaction, was studied using mdr1a(-) or mdr1a/b(-/-) mice (P-gp-deficient mice) and matched controls.	Triazolam	87-90	phosphoglycolate phosphatase	Mus musculus	28-32
15099443-6	2004	On the other hand, MP inhibited the CYP3A-mediated triazolam hydroxylations in a concentration-dependent manner.	Triazolam	51-60	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	36-41
15129163-4	2004	Triazolam also slowed the decay of spontaneous inhibitory synaptic currents, reduced the amplitude of fEPSPs elicited during a theta burst and reduced the magnitude of LTP in hippocampal CA1 neurones in vitro.	Triazolam	0-9	carbonic anhydrase 1	Homo sapiens	187-190
14742746-2	2004	The biotransformation of triazolam to its primary hydroxylated products, 4-OH-TRZ (triazolam) and alpha-OH-TRZ, was used as a marker of CYP3A activity in rat liver and intestine.	Triazolam	25-34	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	136-141
15370962-0	2004	Role of CYP3A enzymes in the biotransformation of triazolam in rat liver.	Triazolam	50-59	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	8-13
12814972-1	2003	Midazolam, triazolam (TRZ), testosterone, and nifedipine have all been widely used as probes for in vitro metabolism of CYP3A.	Triazolam	11-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-125
14985144-7	2004	Compared with vehicle control, CYP3A activity in liver microsomes (intrinsic clearance for triazolam hydroxylation in vitro) was increased by a factor of 2-4 by RIT, and by 10-14-fold by DEX.	Triazolam	91-100	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	31-36
12814972-1	2003	Midazolam, triazolam (TRZ), testosterone, and nifedipine have all been widely used as probes for in vitro metabolism of CYP3A.	Triazolam	22-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-125
12814972-3	2003	Recombinant CYP3A4 and CYP3A5 (rCYP3A4 and rCYP3A5) both produced 1-OH and 4-OH metabolites from midazolam and triazolam, 6 beta-hydroxytestosterone from testosterone, and oxidized nifedipine from nifedipine.	Triazolam	111-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-18
12814972-3	2003	Recombinant CYP3A4 and CYP3A5 (rCYP3A4 and rCYP3A5) both produced 1-OH and 4-OH metabolites from midazolam and triazolam, 6 beta-hydroxytestosterone from testosterone, and oxidized nifedipine from nifedipine.	Triazolam	111-120	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	23-29
12814972-10	2003	Thus, CYP3A4 and CYP3A5 both contribute to midazolam, triazolam, testosterone, and nifedipine biotransformation in HLMs, with CYP3A5 being metabolically less active than CYP3A4 in general.	Triazolam	54-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-12
12814972-10	2003	Thus, CYP3A4 and CYP3A5 both contribute to midazolam, triazolam, testosterone, and nifedipine biotransformation in HLMs, with CYP3A5 being metabolically less active than CYP3A4 in general.	Triazolam	54-63	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	17-23
11158730-14	2001	Inhibition of one or both CYP2C19 and CYP3A isoforms is the likely mechanism by which INH slows the elimination of coadministered drugs, including phenytoin, carbamazepine, diazepam, triazolam, and primidone.	Triazolam	183-192	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	26-33
12724045-5	2003	At 250 microM triazolam (the CYP3A index substrate), the mean (+/- s.e., n = 4) IC50 versus triazolam alpha-hydroxylation (where IC50 is the concentration producing a 50% decrement in reaction velocity) was 7.3 (+/- 0.5) microM.	Triazolam	14-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-34
12724045-5	2003	At 250 microM triazolam (the CYP3A index substrate), the mean (+/- s.e., n = 4) IC50 versus triazolam alpha-hydroxylation (where IC50 is the concentration producing a 50% decrement in reaction velocity) was 7.3 (+/- 0.5) microM.	Triazolam	92-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-34
12537513-14	2003	The only substantive interactions observed were with ethinylestradiol and triazolam, apparently through induction of CYP3A4, primarily in the gastrointestinal system.	Triazolam	74-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	117-123
12404077-0	2002	Selective antagonism of the ataxic effects of zolpidem and triazolam by the GABAA/alpha1-preferring antagonist beta-CCt in squirrel monkeys.	Triazolam	59-68	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1	Mus musculus	76-81
12404077-0	2002	Selective antagonism of the ataxic effects of zolpidem and triazolam by the GABAA/alpha1-preferring antagonist beta-CCt in squirrel monkeys.	Triazolam	59-68	t-complex protein 1	Mus musculus	116-119
11823757-10	2002	Therefore significant metabolic drug-drug interactions are most likely to occur with compounds (such as triazolam) that undergo significant gastrointestinal CYP3A4/5-mediated first-pass metabolism.	Triazolam	104-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	157-163
12751920-14	2003	While triazolam and midazolam are biotransformed almost entirely via CYP3A4, the newer hypnosedatives are biotransformed by several CYP isozymes in addition to CYP3A4, resulting in CYP3A4 inhibitors and inducers having a lesser effect on their biotransformation.	Triazolam	6-15	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
12751920-14	2003	While triazolam and midazolam are biotransformed almost entirely via CYP3A4, the newer hypnosedatives are biotransformed by several CYP isozymes in addition to CYP3A4, resulting in CYP3A4 inhibitors and inducers having a lesser effect on their biotransformation.	Triazolam	6-15	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
11981598-0	2002	Role of GABAA/benzodiazepine receptors containing alpha 1 and alpha 5 subunits in the discriminative stimulus effects of triazolam in squirrel monkeys.	Triazolam	121-130	adrenoceptor alpha 1D	Homo sapiens	50-69
12579961-0	2002	[Identification of estazolam, alprazolam and triazolam in human urine by LC/MSn].	Triazolam	45-54	moesin	Homo sapiens	76-79
12579961-1	2002	AIM: To investigate the fragmentation behavior of triazolobenzodiazepines and to develop a specific, sensitive and rapid LC/MSn assay for simultaneous determination of estazolam, alprazolam and triazolam in human urine.	Triazolam	194-203	moesin	Homo sapiens	124-127
11414684-1	2001	The inhibition of CYP3A4-mediated oxidation of triazolam and testosterone was assessed in the presence of a selection of known CYP3A4 substrates and inhibitors.	Triazolam	47-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-24
11414684-4	2001	In additional studies, residual CYP3A4 activity toward testosterone and triazolam hydroxylation was measured after pretreatment with the CYP3A4 mechanism based inhibitor, midazolam.	Triazolam	72-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
11158730-14	2001	Inhibition of one or both CYP2C19 and CYP3A isoforms is the likely mechanism by which INH slows the elimination of coadministered drugs, including phenytoin, carbamazepine, diazepam, triazolam, and primidone.	Triazolam	183-192	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-43
10935688-10	2000	The findings are consistent with the complete dependence of triazolam clearance on CYP3A activity, compared with the partial dependence of zolpidem clearance on CYP3A.	Triazolam	60-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-88
11124232-7	2001	To explain these kinetic observations, a two-site binding model is proposed in which triazolam is hypothesized to bind within the CYP3A4 active site in spatially distinct orientations, which may lead to the formation of either the 1"-hydroxytriazolam or 4-hydroxytriazolam.	Triazolam	85-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	130-136
10997940-3	2000	In addition, an investigation of MgCl(2) effects on CYP3A4-mediated metabolism of triazolam revealed that 10 mM MgCl(2) increased the apparent K(m) of triazolam 4-hydroxylation from 83 to 173 microM and reduced the V(max) for the reaction from 3.4 to 2.4 min(-1).	Triazolam	82-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-58
10997940-3	2000	In addition, an investigation of MgCl(2) effects on CYP3A4-mediated metabolism of triazolam revealed that 10 mM MgCl(2) increased the apparent K(m) of triazolam 4-hydroxylation from 83 to 173 microM and reduced the V(max) for the reaction from 3.4 to 2.4 min(-1).	Triazolam	151-160	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-58
10952482-1	2000	OBJECTIVE: Biotransformation of triazolam to its alpha-hydroxy and 4-hydroxy metabolites by human liver microsomes in vitro was used as an index of human cytochrome P450 3A (CYP3A) activity.	Triazolam	32-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	154-172
10952482-1	2000	OBJECTIVE: Biotransformation of triazolam to its alpha-hydroxy and 4-hydroxy metabolites by human liver microsomes in vitro was used as an index of human cytochrome P450 3A (CYP3A) activity.	Triazolam	32-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-179
11124232-0	2001	Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site.	Triazolam	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
10773013-9	2000	The complete dependence of triazolam clearance on CYP3A activity, as opposed to the mixed CYP participation in zolpidem clearance, may explain the differing sex effects on clearance of the two compounds.	Triazolam	27-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-55
10640299-1	2000	Midazolam (MDZ) and triazolam (TRZ) hydroxylation, reactions considered to be cytochrome P-4503A (CYP3A)-mediated in humans, were examined in mouse and human liver microsomes.	Triazolam	20-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-103
10870985-0	2000	Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.	Triazolam	42-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-152
10870985-1	2000	PURPOSE: To quantitatively predict the in vivo interaction between triazolam and erythromycin, which involves mechanism-based inhibition of CYP3A4, from in vitro studies using human liver microsomes (HLM) and recombinant human CYP3A4 (REC).	Triazolam	67-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	140-146
10870985-1	2000	PURPOSE: To quantitatively predict the in vivo interaction between triazolam and erythromycin, which involves mechanism-based inhibition of CYP3A4, from in vitro studies using human liver microsomes (HLM) and recombinant human CYP3A4 (REC).	Triazolam	67-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	227-233
10870985-1	2000	PURPOSE: To quantitatively predict the in vivo interaction between triazolam and erythromycin, which involves mechanism-based inhibition of CYP3A4, from in vitro studies using human liver microsomes (HLM) and recombinant human CYP3A4 (REC).	Triazolam	67-76	zinc finger DHHC-type palmitoyltransferase 2	Homo sapiens	235-238
10870985-2	2000	METHODS: HLM or REC was preincubated with erythromycin in the presence of NADPH and then triazolam was added.	Triazolam	89-98	zinc finger DHHC-type palmitoyltransferase 2	Homo sapiens	16-19
10870985-8	2000	Based on the kinetic parameters obtained using HLM and REC, the AUCpo of triazolam was predicted to increase 2.0- and 2.6-fold, respectively, following oral administration of erythromycin (333 mg t.i.d.	Triazolam	73-82	zinc finger DHHC-type palmitoyltransferase 2	Homo sapiens	55-58
10870985-10	2000	CONCLUSIONS: In vivo interaction between triazolam and erythromycin was successfully predicted from in vitro data based on a PBPK model involving a mechanism-based inhibition of CYP3A4.	Triazolam	41-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	178-184
10640299-1	2000	Midazolam (MDZ) and triazolam (TRZ) hydroxylation, reactions considered to be cytochrome P-4503A (CYP3A)-mediated in humans, were examined in mouse and human liver microsomes.	Triazolam	31-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-103
10546924-0	1999	Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam.	Triazolam	103-112	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-92
10602344-8	1999	High-dose administration of diazepam (10 mg kg-1) or triazolam (1 mg kg-1) reduced mPer1 mRNA level 1 h after treatment in the cerebellum.	Triazolam	53-62	period circadian clock 1	Mus musculus	83-88
10230766-2	1999	The in vitro kinetic parameters of CYP3A-mediated metabolism of midazolam (MDZ), triazolam (TRZ), and dexamethasone (DEX) were studied in liver microsomes from three mrdrla(-/-) mice, one mdrla/b(-/-) mouse, and mdrla/b(+/+) controls.	Triazolam	81-90	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	35-40
10383917-5	1999	At the substrate concentration of 20 microM, which approximated the apparent KM value, sulfaphenazole (CYP2C9 inhibitor) and triazolam (CYP3A substrate) reduced the N-demethylation activities by 20 to 35% in human liver microsomes, whereas the inhibition induced by mephenytoin (CYP2C19 substrate) or quinidine (CYP2D6 inhibitor) was marginal.	Triazolam	125-134	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	103-109
10383917-5	1999	At the substrate concentration of 20 microM, which approximated the apparent KM value, sulfaphenazole (CYP2C9 inhibitor) and triazolam (CYP3A substrate) reduced the N-demethylation activities by 20 to 35% in human liver microsomes, whereas the inhibition induced by mephenytoin (CYP2C19 substrate) or quinidine (CYP2D6 inhibitor) was marginal.	Triazolam	125-134	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	279-286
10383917-5	1999	At the substrate concentration of 20 microM, which approximated the apparent KM value, sulfaphenazole (CYP2C9 inhibitor) and triazolam (CYP3A substrate) reduced the N-demethylation activities by 20 to 35% in human liver microsomes, whereas the inhibition induced by mephenytoin (CYP2C19 substrate) or quinidine (CYP2D6 inhibitor) was marginal.	Triazolam	125-134	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	312-318
10230766-0	1999	Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes.	Triazolam	77-86	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	10-28
10230766-0	1999	Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes.	Triazolam	77-86	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	30-35
10383920-8	1999	However, rokitamycin, LMA7, erythromycin, and clarithromycin inhibited the CYP3A4-catalyzed triazolam alpha-hydroxylation with IC50 (Ki) values of 5.8 (2.0), 40, 33 (20), and 56 (43) microM, respectively.	Triazolam	92-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
10230766-2	1999	The in vitro kinetic parameters of CYP3A-mediated metabolism of midazolam (MDZ), triazolam (TRZ), and dexamethasone (DEX) were studied in liver microsomes from three mrdrla(-/-) mice, one mdrla/b(-/-) mouse, and mdrla/b(+/+) controls.	Triazolam	92-95	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	35-40
10459684-0	1999	Effects of a small dose of triazolam on P300.	Triazolam	27-36	E1A binding protein p300	Homo sapiens	40-44
9698298-4	1998	The BN N-dealkylation activities in 10 human liver microsomal preparations were strongly correlated with microsomal CYP3A-specific metabolic reactions, i.e. triazolam 1"-hydroxylation (r = 0.954), midazolam 1"-hydroxylation (r = 0.928), and testosterone 6beta-hydroxylation (r = 0.897).	Triazolam	157-166	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-121
9783333-1	1998	The effects of short-term use of a small dose of dexamethasone on the pharmacokinetics and pharmacodynamics of the CYP3A4 substrate, triazolam, were examined.	Triazolam	133-142	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-121
9783333-9	1998	Although dexamethasone had only small effects on the pharmacokinetics and pharmacodynamics of triazolam in the present study, higher doses or prolonged use of dexamethasone might cause a more pronounced induction of CYP3A4.	Triazolam	94-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	216-222
9765359-4	1998	Coincubation with triazolam showed that delavirdine caused a time- and NADPH-dependent loss of CYP3A4 activity in human liver microsomes as measured by triazolam 1"-hydroxylation.	Triazolam	18-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
9765359-4	1998	Coincubation with triazolam showed that delavirdine caused a time- and NADPH-dependent loss of CYP3A4 activity in human liver microsomes as measured by triazolam 1"-hydroxylation.	Triazolam	152-161	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
9333111-2	1997	Erythromycin and itraconazole are potent inhibitors of CYP3A4, and they increase plasma concentrations and effects of certain drugs, for example, oral midazolam and triazolam.	Triazolam	165-174	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-61
9676900-9	1998	In addition, the BZD agonist triazolam (0.05-0.25 mg/kg) also produced a flumazenil- and picrotoxin-sensitive hyperphagic effects, thereby suggesting the changes in feeding behavior by neurosteroids represent GABA-A receptor mediated hyperphagic action.	Triazolam	29-38	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1	Mus musculus	209-215
9626922-2	1998	Itraconazole strongly interacts with many substrates of CYP3A4 such as midazolam and triazolam.	Triazolam	85-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
8612379-1	1996	BACKGROUND: Triazolam is metabolized by CYP3A4.	Triazolam	12-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
9263374-0	1997	Single-dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P4502C19 (CYP2C19) activity.	Triazolam	58-67	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	83-102
9263374-0	1997	Single-dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P4502C19 (CYP2C19) activity.	Triazolam	58-67	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	104-111
9263374-1	1997	Previous studies have suggested that triazolam is at least partly metabolized by cytochrome P4503A4 (CYP3A4).	Triazolam	37-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-99
9263374-1	1997	Previous studies have suggested that triazolam is at least partly metabolized by cytochrome P4503A4 (CYP3A4).	Triazolam	37-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-107
9263374-2	1997	However, no study has examined the relationship between the metabolism of triazolam and CYP2C19, which is involved in the metabolism of diazepam.	Triazolam	74-83	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	88-95
9146848-1	1997	AIMS: Triazolam, a triazolobenzodiazepine hypnotic agent, is metabolized by CYP3A4.	Triazolam	6-15	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82
9024169-1	1997	BACKGROUND: Triazolam is metabolized predominantly by cytochrome P450 3A4 (CYP3A4).	Triazolam	12-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-73
9024169-1	1997	BACKGROUND: Triazolam is metabolized predominantly by cytochrome P450 3A4 (CYP3A4).	Triazolam	12-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
9024169-12	1997	This is most likely due to increased metabolism of triazolam after induction of CYP3A4 in the gut wall and liver by rifampin.	Triazolam	51-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
9129558-2	1997	Itraconazole strongly interacts with some of the substrates of CYP3A4 (e.g., terfenadine, triazolam and lovastatin); hence it is important to uncover the possible interaction of itraconazole with felodipine.	Triazolam	90-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-69
8730978-17	1996	Triazolam and probably other drugs metabolized by CYP3A4 can be used in normal doses with terbinafine.	Triazolam	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
8612379-11	1996	Prescription of triazolam should be avoided if a patient is using diltiazem or other potent inhibitors of CYP3A.	Triazolam	16-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-111
8610817-8	1996	Cytochrome P450 3A4 metabolizes terfenadine, astemizole, carbamazepine, alprazolam, triazolam, and other benzodiazepines.	Triazolam	84-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-19
8830062-3	1995	The metabolism of triazolam is dependent on cytochrome P450 3A4, and because nefazodone has been shown in vitro to be an inhibitor of this isoenzyme, this study was conducted to assess the potential for an interaction between the two drugs.	Triazolam	18-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-63
8824695-0	1996	Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity.	Triazolam	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-102
8830062-13	1995	The increase in triazolam concentrations in plasma appears to be attributable to the inhibition of cytochrome P450 3A4 metabolism by nefazodone.	Triazolam	16-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-118
7995001-1	1994	BACKGROUND: Triazolam is metabolized by CYP3A4 isozyme.	Triazolam	12-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
7852841-10	1995	In cells from both control and endotoxemic rats, the effects of PAF on intracellular pH were inhibited by the specific PAF antagonist triazolam.	Triazolam	134-143	PCNA clamp associated factor	Rattus norvegicus	64-67
7852841-10	1995	In cells from both control and endotoxemic rats, the effects of PAF on intracellular pH were inhibited by the specific PAF antagonist triazolam.	Triazolam	134-143	PCNA clamp associated factor	Rattus norvegicus	119-122
7995001-2	1994	Ketoconazole and itraconazole may seriously interact with some of the substrates of CYP3A4 (e.g., terfenadine); hence their possible interaction with triazolam in humans is important to uncover.	Triazolam	150-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90
7995001-11	1994	Inhibition of CYP3A4 during the absorption and elimination phases of triazolam seems to explain the interaction observed.	Triazolam	69-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
1329159-0	1992	[Changes in plasma cortisol and ACTH caused by diazepam, bromazepam, triazolam, and alprazolam in oral premedication].	Triazolam	69-78	proopiomelanocortin	Homo sapiens	32-36
7871096-0	1994	Discriminating the effects of triazolam on stimulus and response processing by means of reaction time and P300 latency.	Triazolam	30-39	E1A binding protein p300	Homo sapiens	106-110
7901754-2	1993	We found in this study that even the beta 2 gamma 2 subtype displays gamma-aminobutyric acid-induced Cl- currents that are potentiated by triazolam (a triazolobenzodiazepine).	Triazolam	138-147	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	37-43
8396125-5	1993	The calcium response to PAF, which was largely due to mobilization of calcium from intracellular stores, was found to be dose-dependent in the nanomolar concentration range and inhibitable by the PAF receptor antagonist triazolam.	Triazolam	220-229	PCNA clamp associated factor	Rattus norvegicus	24-27
8396125-5	1993	The calcium response to PAF, which was largely due to mobilization of calcium from intracellular stores, was found to be dose-dependent in the nanomolar concentration range and inhibitable by the PAF receptor antagonist triazolam.	Triazolam	220-229	PCNA clamp associated factor	Rattus norvegicus	196-199
8383168-7	1993	In both cell types, triazolam and alprazolam, two PAF antagonists, and the calcium channel blocker verapamil inhibited PAF-induced calcium mobilization.	Triazolam	20-29	PCNA clamp associated factor	Homo sapiens	50-53
8383168-7	1993	In both cell types, triazolam and alprazolam, two PAF antagonists, and the calcium channel blocker verapamil inhibited PAF-induced calcium mobilization.	Triazolam	20-29	PCNA clamp associated factor	Homo sapiens	119-122
8448651-4	1993	Tz-induced Fos-labeled nuclei were found in superior colliculi, Edinger-Westphal nuclei (EW) and dorsal tegmental nuclei (DTg), but not in the RN.	Triazolam	0-2	proto-oncogene c-Fos	Mesocricetus auratus	11-14
1642641-2	1992	The clearance of quinidine, midazolam, triazolam, erythromycin, and lidocaine declines with age; these drugs are metabolized by the isoform, CYP3A.	Triazolam	39-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-146
1324692-7	1992	PAF antagonists (WEB 2086, CV 3988, triazolam, and SRI 63,441) blocked the action of the four ether lipids on platelets, while SRI 63,441 blocked the antineoplastic activity of the ether lipids on WEHI-3B and HL-60 cells.	Triazolam	36-45	patchy fur	Mus musculus	0-3
2230061-4	1990	Triazolam-treated patients presented significantly more day-time-interdose anxiety than zopiclone as assessed by the weekly HARS and Clinical Global Assessment of Anxiety.	Triazolam	0-9	histidyl-tRNA synthetase 1	Homo sapiens	124-128
1814557-5	1991	Given that hamsters bearing SCN grafts have limited neural connections between the host brain and transplanted SCN tissue, the results suggest that a site outside the SCN, with afferents to these nuclei, mediates the phase-shifting effect of Tz and of exercise.	Triazolam	242-244	sorcin	Homo sapiens	28-31
1814557-5	1991	Given that hamsters bearing SCN grafts have limited neural connections between the host brain and transplanted SCN tissue, the results suggest that a site outside the SCN, with afferents to these nuclei, mediates the phase-shifting effect of Tz and of exercise.	Triazolam	242-244	sorcin	Homo sapiens	111-114
1814557-5	1991	Given that hamsters bearing SCN grafts have limited neural connections between the host brain and transplanted SCN tissue, the results suggest that a site outside the SCN, with afferents to these nuclei, mediates the phase-shifting effect of Tz and of exercise.	Triazolam	242-244	sorcin	Homo sapiens	111-114
2356395-11	1990	Irrespective of the magnitude of the nocturnal elevation, morning PRL levels were slightly but consistently higher after triazolam treatment than under basal conditions.	Triazolam	121-130	prolactin	Homo sapiens	66-69
3579913-2	1987	The benzodiazepines alprazolam and triazolam, but not diazepam (1-10 microM), inhibit PAF induced aggregation but have no effect on aggregation induced by other platelet agonists such as ADP, epinephrine and collagen.	Triazolam	35-44	PCNA clamp associated factor	Homo sapiens	86-89
2519888-6	1989	In decreasing order of potency, the following PAF-acether antagonists inhibited the change in platelet cytosolic free calcium elicited by 10 nM PAF-acether: L-652,731, kadsurenone, triazolam, diltiazem and alprazolam.	Triazolam	181-190	PCNA clamp associated factor	Homo sapiens	46-49
2519888-6	1989	In decreasing order of potency, the following PAF-acether antagonists inhibited the change in platelet cytosolic free calcium elicited by 10 nM PAF-acether: L-652,731, kadsurenone, triazolam, diltiazem and alprazolam.	Triazolam	181-190	PCNA clamp associated factor	Homo sapiens	144-147
3251503-6	1988	Nocturnal alertness, as measured by subjective report and objective nap latency test, increased significantly following the use of triazolam, 0.25 and 0.50 mg, for the day sleep period.	Triazolam	131-140	catenin beta like 1	Homo sapiens	68-71
3046952-4	1988	BN 52021 and another unrelated PAF antagonist, triazolam, partially reduced the restraint-stress-induced gastric damage in young female, but not male, rats.	Triazolam	47-56	PCNA clamp associated factor	Rattus norvegicus	31-34
2845442-1	1988	The abilities of 4 triazolobenzodiazepines, adinazolam, alprazolam, estazolam and triazolam, to inhibit thyrotropin-releasing hormone (TRH) receptor binding and to antagonize the narcoleptic effects of TRH were examined.	Triazolam	82-91	thyrotropin releasing hormone receptor	Homo sapiens	104-148
2845442-1	1988	The abilities of 4 triazolobenzodiazepines, adinazolam, alprazolam, estazolam and triazolam, to inhibit thyrotropin-releasing hormone (TRH) receptor binding and to antagonize the narcoleptic effects of TRH were examined.	Triazolam	82-91	thyrotropin releasing hormone	Homo sapiens	135-138
3694533-3	1987	The negative inotropic effect of PAF was, however, antagonized by drugs known to inhibit PAF-induced platelet aggregation: the order of relative potency was SRI 63-441 greater than CV-3988 greater than alprazolam greater than or equal to triazolam; i.e., the same order in which these compounds antagonize the effects of PAF on platelets.	Triazolam	238-247	PCNA clamp associated factor	Homo sapiens	33-36
3694533-3	1987	The negative inotropic effect of PAF was, however, antagonized by drugs known to inhibit PAF-induced platelet aggregation: the order of relative potency was SRI 63-441 greater than CV-3988 greater than alprazolam greater than or equal to triazolam; i.e., the same order in which these compounds antagonize the effects of PAF on platelets.	Triazolam	238-247	PCNA clamp associated factor	Homo sapiens	89-92
3694533-3	1987	The negative inotropic effect of PAF was, however, antagonized by drugs known to inhibit PAF-induced platelet aggregation: the order of relative potency was SRI 63-441 greater than CV-3988 greater than alprazolam greater than or equal to triazolam; i.e., the same order in which these compounds antagonize the effects of PAF on platelets.	Triazolam	238-247	PCNA clamp associated factor	Homo sapiens	89-92
35351776-13	2022	The canine CYP2B11 was found to appreciably contribute to hydroxylation of midazolam, alprazolam and triazolam, the well-known probes for human CYP3A.	Triazolam	101-110	cytochrome P450 2B11	Canis lupus familiaris	11-18
35351776-13	2022	The canine CYP2B11 was found to appreciably contribute to hydroxylation of midazolam, alprazolam and triazolam, the well-known probes for human CYP3A.	Triazolam	101-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-149
3579913-3	1987	The IC50 for aggregation by PAF (4 nM) in GFP is 1 microM for both alprazolam and triazolam.	Triazolam	82-91	PCNA clamp associated factor	Homo sapiens	28-31
3579913-7	1987	Alprazolam and triazolam, but not diazepam, caused competitive displacement of 3H-PAF from specific binding sites of GFP.	Triazolam	15-24	PCNA clamp associated factor	Homo sapiens	82-85
3579913-10	1987	These results are consistent with the interpretation that the specific inhibition of PAF induced platelet aggregation by alprazolam and triazolam, respectively, is due to competitive inhibition of binding of PAF to its receptor.	Triazolam	136-145	PCNA clamp associated factor	Homo sapiens	85-88
3579913-10	1987	These results are consistent with the interpretation that the specific inhibition of PAF induced platelet aggregation by alprazolam and triazolam, respectively, is due to competitive inhibition of binding of PAF to its receptor.	Triazolam	136-145	PCNA clamp associated factor	Homo sapiens	208-211
34013847-3	2021	The plasma concentrations ratios of alpha-hydroxytriazolam and 4-hydroxytriazolam to triazolam in portal blood were significantly decreased by multiple administration of clarithromycin in CYP3A-humanised mice.These results suggest that intestinal CYP3A activity was inhibited by macrolide antibiotics in CYP3A-humanised mice in vitro and in vivo.	Triazolam	49-58	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	188-193
2893525-3	1987	We have found that the psychotropic triazolobenzodiazepine drugs, alprazolam and triazolam, potently (IC50 less than 1 microM) inhibit PAF-induced shape change, aggregation and secretion of human platelets.	Triazolam	81-90	PCNA clamp associated factor	Homo sapiens	135-138
6150550-3	1984	It was found that in washed human platelets the psychotropic triazolobenzodiazepine drugs alprazolam and triazolam potently inhibited PAF-induced changes in shape, aggregation, and secretion.	Triazolam	105-114	PCNA clamp associated factor	Homo sapiens	134-137
6142705-2	1984	Polarographic determination (DPP and CRP) of triazolam in plasma and serum].	Triazolam	45-54	C-reactive protein	Homo sapiens	37-40
3587377-1	1987	The triazolodiazepines brotizolam, triazolam and alprazolam inhibited PAF-induced human platelet aggregation in vitro (IC50 = 0.54, 7.6 and 13.7 microM, respectively) but showed only a weak or no effect against other aggregating agents (ADP, adrenaline, collagen, serotonin, arachidonic acid).	Triazolam	35-44	PCNA clamp associated factor	Homo sapiens	70-73
3587377-4	1987	Brotizolam and triazolam also inhibited PAF-induced human neutrophil aggregation in vitro, with IC50-values 0.21 and 6.6 microM, respectively.	Triazolam	15-24	PCNA clamp associated factor	Homo sapiens	40-43
3587377-14	1987	Triazolam inhibited these effects of PAF at doses of 50 to 200 mg/kg p.o.	Triazolam	0-9	PCNA clamp associated factor	Homo sapiens	37-40
3587377-17	1987	In conclusion, these results show that triazolodiazepines, like brotizolam and triazolam, are potent inhibitors of PAF-induced effects in vitro and in vivo.	Triazolam	79-88	PCNA clamp associated factor	Homo sapiens	115-118
3081931-2	1986	We investigated, therefore, whether a single dose of triazolam, a short-acting benzodiazepine, and flurazepam, a long-acting one, could influence the response of prolactin (PRL), growth hormone (GH) and cortisol to a mild hypoglycemic stress in young healthy volunteers.	Triazolam	53-62	prolactin	Homo sapiens	162-171
3081931-2	1986	We investigated, therefore, whether a single dose of triazolam, a short-acting benzodiazepine, and flurazepam, a long-acting one, could influence the response of prolactin (PRL), growth hormone (GH) and cortisol to a mild hypoglycemic stress in young healthy volunteers.	Triazolam	53-62	prolactin	Homo sapiens	173-176
3081931-2	1986	We investigated, therefore, whether a single dose of triazolam, a short-acting benzodiazepine, and flurazepam, a long-acting one, could influence the response of prolactin (PRL), growth hormone (GH) and cortisol to a mild hypoglycemic stress in young healthy volunteers.	Triazolam	53-62	growth hormone 1	Homo sapiens	179-193
2859867-0	1985	Coma caused by trivial triazolam overdose.	Triazolam	23-32	COMA	Homo sapiens	0-4
34013847-4	2021	The plasma concentrations of triazolam and its metabolites in the portal blood of CYP3A-humanised mice would be useful for direct evaluation of intestinal CYP3A-mediated drug-drug interactions.	Triazolam	29-38	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	82-87
34013847-4	2021	The plasma concentrations of triazolam and its metabolites in the portal blood of CYP3A-humanised mice would be useful for direct evaluation of intestinal CYP3A-mediated drug-drug interactions.	Triazolam	29-38	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	155-160
33959005-1	2021	In order to develop improved anxiolytic drugs, 8-substituted analogs of triazolam were synthesized in an effort to discover compounds with selectivity for alpha2/alpha3 subunit-containing GABAA subtypes.	Triazolam	72-81	UDP glucuronosyltransferase 1 family, polypeptide A7C	Rattus norvegicus	155-168
31455676-4	2019	Oral administration of the human PXR activator rifampicin increased hepatic expression of CYP3A4 mRNA and triazolam (TRZ) 1"- and 4-hydroxylation activities, CYP3A probe activities, in the liver and intestine microsomes of hCYP3A-MAC/hPXR mice.	Triazolam	106-115	nuclear receptor subfamily 1 group I member 2	Homo sapiens	33-36
33863817-7	2021	In vivo CYP3A activity was monitored by measuring changes in the exposure of the CYP3A probe substrate triazolam.	Triazolam	103-112	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	8-13
33863817-7	2021	In vivo CYP3A activity was monitored by measuring changes in the exposure of the CYP3A probe substrate triazolam.	Triazolam	103-112	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-86
31455676-11	2019	Expression of CYP3A4 and metabolism of triazolam, a typical CYP3A substrate, in the liver of CYP3A/PXR-humanized mice were enhanced in response to rifampicin, a typical human PXR activator.	Triazolam	39-48	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	60-65
33191904-5	2021	MATERIALS AND METHODS: An in silico DDI study was conducted using a population-based physiological pharmacokinetic simulator to estimate the CR of cytochrome P450 (CYP)3A4 for zolpidem, sildenafil, omeprazole, triazolam, and repaglinide.	Triazolam	210-219	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	147-171
31455676-4	2019	Oral administration of the human PXR activator rifampicin increased hepatic expression of CYP3A4 mRNA and triazolam (TRZ) 1"- and 4-hydroxylation activities, CYP3A probe activities, in the liver and intestine microsomes of hCYP3A-MAC/hPXR mice.	Triazolam	117-120	nuclear receptor subfamily 1 group I member 2	Homo sapiens	33-36
31455676-11	2019	Expression of CYP3A4 and metabolism of triazolam, a typical CYP3A substrate, in the liver of CYP3A/PXR-humanized mice were enhanced in response to rifampicin, a typical human PXR activator.	Triazolam	39-48	nuclear receptor subfamily 1, group I, member 2	Mus musculus	99-102
31455676-5	2019	The plasma concentration of TRZ after oral dosing was significantly decreased by rifampicin treatment in hCYP3A-MAC/hPXR mice but not in hCYP3A-MAC mice.	Triazolam	28-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
31455676-11	2019	Expression of CYP3A4 and metabolism of triazolam, a typical CYP3A substrate, in the liver of CYP3A/PXR-humanized mice were enhanced in response to rifampicin, a typical human PXR activator.	Triazolam	39-48	nuclear receptor subfamily 1 group I member 2	Homo sapiens	175-178
31455676-6	2019	In addition, mass spectrometry imaging analysis showed that rifampicin treatment increased the formation of hydroxy TRZ in the intestine of hCYP3A-MAC/hPXR mice after oral dosing of TRZ.	Triazolam	116-119	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	140-146
31455676-12	2019	Enhancement of triazolam metabolism in the intestine of CYP3A/PXR-humanized mice was firstly shown by combination of mass spectrometry imaging of sliced intestine and liquid chromatography with tandem mass spectrometry analysis of metabolite concentration in portal blood after oral dosing of triazolam.	Triazolam	15-24	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	56-61
31455676-6	2019	In addition, mass spectrometry imaging analysis showed that rifampicin treatment increased the formation of hydroxy TRZ in the intestine of hCYP3A-MAC/hPXR mice after oral dosing of TRZ.	Triazolam	182-185	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	140-146
31455676-12	2019	Enhancement of triazolam metabolism in the intestine of CYP3A/PXR-humanized mice was firstly shown by combination of mass spectrometry imaging of sliced intestine and liquid chromatography with tandem mass spectrometry analysis of metabolite concentration in portal blood after oral dosing of triazolam.	Triazolam	15-24	nuclear receptor subfamily 1, group I, member 2	Mus musculus	62-65
31455676-11	2019	Expression of CYP3A4 and metabolism of triazolam, a typical CYP3A substrate, in the liver of CYP3A/PXR-humanized mice were enhanced in response to rifampicin, a typical human PXR activator.	Triazolam	39-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
31455676-12	2019	Enhancement of triazolam metabolism in the intestine of CYP3A/PXR-humanized mice was firstly shown by combination of mass spectrometry imaging of sliced intestine and liquid chromatography with tandem mass spectrometry analysis of metabolite concentration in portal blood after oral dosing of triazolam.	Triazolam	293-302	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	56-61
31455676-12	2019	Enhancement of triazolam metabolism in the intestine of CYP3A/PXR-humanized mice was firstly shown by combination of mass spectrometry imaging of sliced intestine and liquid chromatography with tandem mass spectrometry analysis of metabolite concentration in portal blood after oral dosing of triazolam.	Triazolam	293-302	nuclear receptor subfamily 1, group I, member 2	Mus musculus	62-65
31455676-11	2019	Expression of CYP3A4 and metabolism of triazolam, a typical CYP3A substrate, in the liver of CYP3A/PXR-humanized mice were enhanced in response to rifampicin, a typical human PXR activator.	Triazolam	39-48	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	14-19
28238899-3	2017	Montelukast and ketoconazole showed a potent and concentration-dependent inhibition of CYP2C8-mediated paclitaxel 6alpha-hydroxylation and CYP3A4-mediated triazolam alpha-hydroxylation, respectively, without dependence on the buffer condition.	Triazolam	155-164	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	139-145
29172026-9	2018	A reduction of the enzymatic activity of the UGT2B7 was recorded in the presence of 9 of the 14 drugs under investigation (ketoconazole, miconazole, itraconazole, diclofenac, ibuprofen, clonazepam, lorazepam, lormetazepam, and triazolam), with a consequent significant reduction of the levels of the glucuronide metabolites.	Triazolam	227-236	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	45-51
28393714-6	2017	CYP3A activity was determined as alpha- and 4-hydroxylation activity of triazolam in liver and intestinal microsomes.	Triazolam	72-81	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	0-5
28393714-9	2017	RESULTS: The results showed that triazolam hydroxylation activities and protein levels of CYP3A in the liver were significantly higher in female than in male CYP3A-HAC mice, whereas those in the intestine were not significantly different between the genders.	Triazolam	33-42	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	158-163
30561249-2	2019	To investigate cytochrome P450 3A (CYP3A)-mediated metabolism in vivo, plasma concentrations of triazolam (TRZ) are often monitored as a CYP3A marker in CYP3A-humanised mice.	Triazolam	96-105	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	35-40
27489535-7	2016	In addition, decreased protein expression of GluR1 and GluR4, which are excitatory neurotransmitter receptors, was detected in the hippocampi of mice treated with TZ during the juvenile period.	Triazolam	163-165	glutamate receptor, ionotropic, AMPA1 (alpha 1)	Mus musculus	45-50
27323294-1	2016	Cytochrome P450 (P450) 3A (CYP3A) is an enzyme responsible for the metabolism of therapeutic drugs such as midazolam, nifedipine, testosterone and triazolam.	Triazolam	147-156	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-25
27323294-1	2016	Cytochrome P450 (P450) 3A (CYP3A) is an enzyme responsible for the metabolism of therapeutic drugs such as midazolam, nifedipine, testosterone and triazolam.	Triazolam	147-156	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-32
27489535-7	2016	In addition, decreased protein expression of GluR1 and GluR4, which are excitatory neurotransmitter receptors, was detected in the hippocampi of mice treated with TZ during the juvenile period.	Triazolam	163-165	glutamate receptor, ionotropic, AMPA4 (alpha 4)	Mus musculus	55-60
26290405-0	2016	Effect of buffer conditions on CYP2C8-mediated paclitaxel 6alpha-hydroxylation and CYP3A4-mediated triazolam alpha- and 4-hydroxylation by human liver microsomes.	Triazolam	99-108	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
22659374-4	2012	Triazolam, which is a substrate of Cyp3a, was intraperitoneally administered to the mice in the HF group.	Triazolam	0-9	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	35-40
25533998-9	2015	Ramelteon and triazolam significantly increased the time to complete of Trail-Making Test part A and the environmental area in posturography compared to placebo at 1 and 4 h post-dosing.	Triazolam	14-23	TNF superfamily member 10	Homo sapiens	72-77
25657337-6	2015	In vitro triazolam 4-hydroxylation (probe reaction for CYP3A4) was reduced by >50% in hepatic microsomes from CYP3A4-HBN mice compared with controls.	Triazolam	9-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-61
25657337-6	2015	In vitro triazolam 4-hydroxylation (probe reaction for CYP3A4) was reduced by >50% in hepatic microsomes from CYP3A4-HBN mice compared with controls.	Triazolam	9-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-119
25657337-8	2015	This effect was confirmed by the concentration-dependent restoration of CYP3A4-mediated triazolam turnover and CYP2D6-mediated bufuralol and debrisoquine turnover on addition of Escherichia coli membranes containing recombinant Cyb5.	Triazolam	88-97	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-78
25657337-9	2015	In vivo, the peak plasma concentration and area under the concentration time curve from 0 to 8 hours (AUC0-8 h) of triazolam were increased 4- and 5.7-fold, respectively, in CYP3A4-HBN mice.	Triazolam	115-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180
25359648-7	2014	However, patients taking anticoagulants or cytochrome P450 3A4 substrates (such as clarithromycin, erythromycin, ketoconazole, itraconazole, midazolam and triazolam) in addition to specific vitamin or mineral supplements (vitamins D, E, K, calcium, fluoride, iron, magnesium, selenium or zinc) may face additional challenges.	Triazolam	155-164	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-62
25757928-2	2015	This study evaluated the effects of menthol on the pharmacokinetics of the CYP3A substrate triazolam and the CYP2C substrate phenytoin.	Triazolam	91-100	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	75-80
25757928-4	2015	In addition, the CYP3A metabolic activity for triazolam and the CYP3A expression level in the liver were determined.	Triazolam	46-55	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	17-22
24367698-7	2013	administration of both triazolam (0.03 mg/kg) and ZP (1.0 mg/kg) decreased BDNF protein levels within the HIP relative to vehicle, without any effect on c-Fos.	Triazolam	23-32	brain derived neurotrophic factor	Mus musculus	75-79
23282066-0	2013	Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam.	Triazolam	171-180	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	105-110
22943633-2	2013	METHODS: A 50:50 mixture of lowbush and highbush BBJ was evaluated in vitro as an inhibitor of CYP3A activity (hydroxylation of triazolam and dealkylation of buspirone) and of CYP2C9 activity (flurbiprofen hydroxylation) using human liver microsomes.	Triazolam	128-137	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-100
21561794-4	2011	Results demonstrated that diazepam, triazolam, amitriptyline, mianserin, malathion, fenitrothion, chlorpyrifosmethyl, and probenecid significantly inhibited representative substrates of hOAT1 and para-aminohippuric acid uptake by hOAT1.	Triazolam	36-45	solute carrier family 22 member 6	Homo sapiens	186-191
22447115-5	2012	The formation of metabolites from triazolam, diclofenac and SN-38 was strongly inhibited by co-treatment with a CYP3A inhibitor (ketoconazole), CYP2C9 inhibitor (sulfaphenazole) and UGT1A1 inhibitor (ketoconazole), respectively.	Triazolam	34-43	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	144-150
22447115-5	2012	The formation of metabolites from triazolam, diclofenac and SN-38 was strongly inhibited by co-treatment with a CYP3A inhibitor (ketoconazole), CYP2C9 inhibitor (sulfaphenazole) and UGT1A1 inhibitor (ketoconazole), respectively.	Triazolam	34-43	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	182-188
21561794-4	2011	Results demonstrated that diazepam, triazolam, amitriptyline, mianserin, malathion, fenitrothion, chlorpyrifosmethyl, and probenecid significantly inhibited representative substrates of hOAT1 and para-aminohippuric acid uptake by hOAT1.	Triazolam	36-45	solute carrier family 22 member 6	Homo sapiens	230-235
20497744-3	2010	Triazolam is primarily metabolized by CYP3A and its plasma concentration is increased remarkably by itraconazole.	Triazolam	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-43
20080160-9	2010	In conclusion, Alprazolam, Bromazepam, Chlordiazepoxide, Clonazepam, Diazepam, Lorazepam, Nitrazepam, Oxazepam, Tetrazepam and Triazolam can be considered as safe drugs in term of their inability to induce PXR- and AhR-dependent cytochrome P450 enzymes CYP1A2 and CYP3A4.	Triazolam	127-136	nuclear receptor subfamily 1 group I member 2	Homo sapiens	206-209
20080160-9	2010	In conclusion, Alprazolam, Bromazepam, Chlordiazepoxide, Clonazepam, Diazepam, Lorazepam, Nitrazepam, Oxazepam, Tetrazepam and Triazolam can be considered as safe drugs in term of their inability to induce PXR- and AhR-dependent cytochrome P450 enzymes CYP1A2 and CYP3A4.	Triazolam	127-136	aryl hydrocarbon receptor	Homo sapiens	215-218
20080160-9	2010	In conclusion, Alprazolam, Bromazepam, Chlordiazepoxide, Clonazepam, Diazepam, Lorazepam, Nitrazepam, Oxazepam, Tetrazepam and Triazolam can be considered as safe drugs in term of their inability to induce PXR- and AhR-dependent cytochrome P450 enzymes CYP1A2 and CYP3A4.	Triazolam	127-136	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	253-259
20080160-9	2010	In conclusion, Alprazolam, Bromazepam, Chlordiazepoxide, Clonazepam, Diazepam, Lorazepam, Nitrazepam, Oxazepam, Tetrazepam and Triazolam can be considered as safe drugs in term of their inability to induce PXR- and AhR-dependent cytochrome P450 enzymes CYP1A2 and CYP3A4.	Triazolam	127-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	264-270
19752211-3	2009	Triazolam was used as a probe drug because it is a highly specific CYP3A substrate and not a P-glycoprotein substrate.	Triazolam	0-9	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	67-72
19752211-4	2009	Triazolam metabolism was profoundly reduced in Cyp3a(-/-) mice both in vitro and in vivo.	Triazolam	0-9	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	47-52
19752211-7	2009	To mimic a drug-drug interaction, we coadministered triazolam with the prototypical CYP3A inhibitor ketoconazole, which increased triazolam exposure in all the CYP3A-proficient mouse strains but not in Cyp3a(-/-) mice.	Triazolam	52-61	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	160-165
19752211-7	2009	To mimic a drug-drug interaction, we coadministered triazolam with the prototypical CYP3A inhibitor ketoconazole, which increased triazolam exposure in all the CYP3A-proficient mouse strains but not in Cyp3a(-/-) mice.	Triazolam	130-139	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	84-89